Pregled bibliografske jedinice broj: 599013
Q192R and L55M pon1 gene polymorphisms associated with peripheral arterial disease
Q192R and L55M pon1 gene polymorphisms associated with peripheral arterial disease // Biochemia Medica 2012 ; 22(3):267-402 ; A17-A204 / Šimundić, AM (ur.).
Zagreb: Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012. str. A165-A165 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 599013 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Q192R and L55M pon1 gene polymorphisms associated with peripheral arterial disease
Autori
Kardum Paro, Mirjana Mariana ; Perkov, S ; Flegar- Meštrić, Z ; Vidjak, V ; Novačić, K ; Barišić, K.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Biochemia Medica 2012 ; 22(3):267-402 ; A17-A204
/ Šimundić, AM - Zagreb : Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2012, A165-A165
Skup
2nd European Joint Congress of European Federation of Clinical Chemistry and Laboratory Medicine (EFCC) and European Union of Medical Specialists (UEMS) / 7th Congress of Croatian Society of Medical Biochemistry and Laboratory Medicine
Mjesto i datum
Dubrovnik, Hrvatska, 10.10.2012. - 13.10.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
pon1 gene polymorphisms; peripheral arterial disease
Sažetak
Background. Development of peripheral arterial disease (PAD) could be due to human serum paraoxonase (pon1) gene polymorphisms or lower catalytic concentrations of serum paraoxonase-1 (PON1). The aim of study was to examine the association of pon1 gene polymorphisms (Q192R and L55M) with the catalytic concentrations of serum PON1 in patients with PAD. Materials and methods. Healthy subjects (118) and patients with angiographically confirmed diagnosis of PAD (110) were investigated. The catalytic concentration of serum PON1 was determined by spectrophotometric method using paraoxon as the supstrate in the presence of NaCl. pon1 gene polymorphisms were determined by PCR-RFLP method accredited according to ISO15189. The assay performance was assessed by interlaboratory specimens exchange. Allele and genotype frequencies were compared by the χ2 or Fisher exact test. Results. For pon1 gene polymorphism Q192R allele and genotype frequency were significantly different betweeen patients with PAD and healthy subjects (both <0, 001), while for pon1 gene polymorphism L55M allele (p= 0, 649) and genotype (p= 0, 327) frequencies did not differ significantly. The catalytic concentrations of serum PON1 were significantly lower in patients with PAD (p=0, 001). In both groups studied the lowest catalytic concentration were found in QQ and MM genotypes of pon1 gene. Conclusions. Lower catalytic concentrations of serum PON1 and Q192R pon1 gene polymorphism could play a role in the development of PAD. Differences in the Q and R allelle frequencies between healthy subjects and patients with PAD may be one of the causes for the reduced catalytic concentrations of serum PON1.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
POVEZANOST RADA
Projekti:
044-0061245-0551 - Novi biokemijski biljezi ateroskleroze u krvožilnim bolestima (Flegar-Meštrić, Zlata, MZOS ) ( CroRIS)
006-0061117-1236 - Posttranskripcijsko utišavanje stresnih proteina pomoću siRNA nanoterapije (Barišić, Karmela, MZOS ) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Profili:
Vinko Vidjak
(autor)
Sonja Perkov
(autor)
Karmela Barišić
(autor)
Mirjana Mariana Kardum-Paro
(autor)
Zlata Flegar-Meštrić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE